Targeting Methyltransferase-Independent Functions of Dot1l in MLL-Rearranged Leukemia

Momentum Fellow (2018-2019)

Florian Perner, MD, Dana-Farber Cancer Institute

Dr. Perner is investigating the mechanisms of resistance to targeted therapy in MLL-rearranged leukemia to identify strategies to improve treatments.

published research

Perner F, Gadrey JY, Xiong Y, Hatton C, Eschle BK, Weiss A, Stauffer F, Gaul C, Tiedt R, Perry JA, Armstrong SA, Krivtsov AV. Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts. Blood. 2020.